Any current/future new fundraising through debt or equity?

The company has announced a rights issue (equity fundraising) which is currently open and closes on June 11, 2024. The rights issue is partly paid, considered more practical under current circumstances. Proceeds from the rights issue are intended primarily for debt reduction and balance sheet strengthening. The promoters are participating in the rights issue and may upsize their entitlements. No specific mention of new debt fundraising was made; rather, the focus is on significant debt reduction from operational cash flow and rights issue proceeds. The company expects improved cash generation

Any current/future capex/capital investment/strategic investment?

The Vizag plant is undergoing a retrofit to manufacture multipurpose products beyond ibuprofen, with completion expected in FY '25. No major new capex is planned except for debottlenecking and annual maintenance. The retrofit will enable additional capacity of about 1,000 kilolitres for future growth. The company aims to increase revenues on the existing asset base to close to around INR 2,500 crores without significant new capex. Focus is on cost optimization, operational efficiency, and maximizing utilization of existing DMFs rather than large-scale new investments. No specific men

Future growth expectations in sales/revenue/volumes?

Solara Active Pharma Sciences targets a revenue of approximately INR 1,500 crores for FY 2025, indicating around 15-16% growth from INR 1,300 crores in FY 2024. Long-term aspirational growth target is a 15% to 18% CAGR over the next 3 to 5 years. New product introductions are expected to contribute INR 150 to INR 200 crores to the FY 2025 revenue guidance. Growth is driven by disciplined sales and marketing actions, cost optimization, and rightsizing of Ibuprofen sales to legacy customers. The company aims to leverage additional capacity at the Vizag facility, post-retrofitting, to support gro

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth of about 15% to 16% for FY25, targeting approximately INR 1,500 crores in revenue with an EBITDA run rate of INR 260-290 crores. The exit EBITDA run rate is expected to approach INR 80 crores by FY25 end. Over 3 to 5 years, Solara targets a top-line CAGR of 15% to 18%, supported by multipurpose capacity from the Vizag facility. Gross margins are expected to improve to around 50-51%, positioning Solara as a better cost earner in the peer group. The focus on disciplined sales, cost optimization, and legacy customer relationships aims to sustain stable operating

Current/ Expected Orderbook/ Pending Orders?

The company has a strong order book as mentioned by Arun Kumar in the call. They are confident in delivering outcomes based on this order book and the right leadership team in place. While specific pending order numbers or values are not disclosed, the management expresses optimism about sustained growth and new product/customer additions. The focus is on disciplined sales and marketing to ramp up sales and improve margins. No mention of significant backlog or order delays; emphasis is on operational reset and execution.

Solara ActiveQ4 FY24Pharmaceuticals & Biotechnology

Solara Active Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹645.65P/E: 66.2Market Cap: ₹3.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Solara Active Pharma Sciences targets a revenue of approximately INR 1,500 crores for FY 2025, indicating around 15-16% growth from INR 1,300 crores in FY 2024.
Long-term aspirational growth target is a 15% to 18% CAGR over the next 3 to 5 years.
New product introductions are expected to contribute INR 150 to INR 200 crores to the FY 2025 revenue guidance.
Growth is driven by disciplined sales and marketing actions, cost optimization, and rightsizing of Ibuprofen sales to legacy customers.
The company aims to leverage additional capacity at the Vizag facility, post-retrofitting, to support growth beyond FY 2025.
Focus is on improving margin profiles and increasing sales of more profitable products, with regulated markets constituting about 75% of sales.

Margin guidance

Category 1

The company expects revenue growth of about 15% to 16% for FY25, targeting approximately INR 1,500 crores in revenue with an EBITDA run rate of INR 260-290 crores.
The exit EBITDA run rate is expected to approach INR 80 crores by FY25 end.
Over 3 to 5 years, Solara targets a top-line CAGR of 15% to 18%, supported by multipurpose capacity from the Vizag facility.
Gross margins are expected to improve to around 50-51%, positioning Solara as a better cost earner in the peer group.
The focus on disciplined sales, cost optimization, and legacy customer relationships aims to sustain stable operating profitability.
New product introductions are projected to contribute INR 150-200 crores to FY25 revenues.
Free cash flow generation and balance sheet de-leveraging are key priorities to support sustained profitability and EPS growth.

See what Solara Active management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company has announced a rights issue (equity fundraising) which is currently open and closes on June 11, 2024.
The rights issue is partly paid, considered more practical under current circumstances.
Proceeds from the rights issue are intended primarily for debt reduction and balance sheet strengthening.
The promoters are participating in the rights issue and may upsize their entitlements.
No specific mention of new debt fundraising was made; rather, the focus is on significant debt reduction from operational cash flow and rights issue proceeds.
The company expects improved cash generation aiding further debt reduction beyond the rights issue amount.
No new major capex-driven borrowings are anticipated; only debottlenecking and maintenance capex are planned.

Order book

The company has a strong order book as mentioned by Arun Kumar in the call.
They are confident in delivering outcomes based on this order book and the right leadership team in place.
While specific pending order numbers or values are not disclosed, the management expresses optimism about sustained growth and new product/customer additions.
The focus is on disciplined sales and marketing to ramp up sales and improve margins.
No mention of significant backlog or order delays; emphasis is on operational reset and execution.

See what Solara Active management said on order book — free account, 30 seconds.

Capex plans

Yes

The Vizag plant is undergoing a retrofit to manufacture multipurpose products beyond ibuprofen, with completion expected in FY '25.
No major new capex is planned except for debottlenecking and annual maintenance.
The retrofit will enable additional capacity of about 1,000 kilolitres for future growth.
The company aims to increase revenues on the existing asset base to close to around INR 2,500 crores without significant new capex.
Focus is on cost optimization, operational efficiency, and maximizing utilization of existing DMFs rather than large-scale new investments.
No specific mention of strategic investments or acquisitions was disclosed in the call.

Track Solara Active — get its next earnings analysis in your feed

How does Solara Active rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSolara Active

Rev 3Mar 1

See where Solara Active sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Solara Active rank in Pharmaceuticals & Biotechnology?

Compare Solara Active against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →